Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) have been assigned a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $187.71.

A number of research analysts recently commented on JAZZ shares. Royal Bank of Canada dropped their price target on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a research note on Wednesday, February 26th. Barclays restated an “overweight” rating and issued a $200.00 target price (up from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Cantor Fitzgerald cut shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and lifted their price objective for the company from $140.00 to $150.00 in a research note on Wednesday, February 26th. HC Wainwright upped their target price on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a “buy” rating in a research note on Monday, March 10th. Finally, UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their target price for the company from $145.00 to $179.00 in a report on Friday, March 7th.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $102.78 on Friday. The business has a fifty day moving average price of $128.14 and a two-hundred day moving average price of $122.36. The stock has a market capitalization of $6.24 billion, a PE ratio of 14.48, a P/E/G ratio of 1.04 and a beta of 0.42. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals has a fifty-two week low of $95.49 and a fifty-two week high of $148.06.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $123.75, for a total value of $185,625.00. Following the sale, the chief executive officer now directly owns 440,307 shares of the company’s stock, valued at approximately $54,487,991.25. This represents a 0.34 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CMO Robert Iannone sold 7,080 shares of Jazz Pharmaceuticals stock in a transaction on Friday, March 7th. The stock was sold at an average price of $138.60, for a total transaction of $981,288.00. Following the transaction, the chief marketing officer now directly owns 82,024 shares of the company’s stock, valued at $11,368,526.40. This represents a 7.95 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 28,736 shares of company stock worth $4,023,305. Insiders own 4.20% of the company’s stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. IFP Advisors Inc acquired a new position in Jazz Pharmaceuticals in the fourth quarter valued at approximately $25,000. Quadrant Capital Group LLC increased its stake in shares of Jazz Pharmaceuticals by 97.1% in the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock valued at $25,000 after acquiring an additional 101 shares in the last quarter. Elequin Capital LP boosted its stake in Jazz Pharmaceuticals by 677.8% during the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock worth $26,000 after acquiring an additional 183 shares in the last quarter. CoreFirst Bank & Trust acquired a new stake in Jazz Pharmaceuticals in the fourth quarter worth $28,000. Finally, Allianz SE acquired a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at about $29,000. Institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.